Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
24.27
-1.23 (-4.82%)
At close: Mar 30, 2026, 4:00 PM EDT
23.81
-0.46 (-1.90%)
After-hours: Mar 30, 2026, 5:19 PM EDT

Damora Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
9.6910.512.691313.74
Research & Development
201.1910.7923.7748.2138.49
Other Operating Expenses
-0.973.45--
Total Operating Expenses
210.8722.2639.9161.2152.23
Operating Income
-210.87-22.26-39.91-61.21-52.23
Total Non-Operating Income (Expense)
1.080.861.56-0.420.48
Pretax Income
-209.79-21.4-38.35-61.62-51.75
Provision for Income Taxes
-0.05-0.04---
Net Income
-209.84-21.44-38.35-61.62-51.75
Net Income to Common
-209.84-21.44-38.35-61.62-51.75
Shares Outstanding (Basic)
11111
Shares Outstanding (Diluted)
11111
Shares Change (YoY)
17.79%8.87%4.58%0.58%452.45%
EPS (Basic)
3.98-18.53-36.08-60.75-51.25
EPS (Diluted)
3.98-18.53-36.08-60.75-51.25
Free Cash Flow
-6.73-18.62-36.91-43.13-52.53
Free Cash Flow Per Share
-4.93-16.09-34.73-42.43-51.99
EBITDA
-210.84-22.08-39.08-60.72-51.79
EBIT
-210.87-22.26-39.91-61.21-52.23
Effective Tax Rate
0.02%0.19%0.00%0.00%0.00%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q